Results 141 to 150 of about 1,675 (195)

Evaluation of selected variables to determine if any had predictive value for, or correlated with, residual symptoms at approximately 12 months after diagnosis and treatment of early Lyme disease

Diagnostic Microbiology and Infectious Disease, 2021
Subjective symptoms may persist after antibiotic treatment of patients with erythema migrans. Selected baseline variables were evaluated to determine if any correlated with symptom persistence to 12 months (PTLDS).
Paul Francis Visintainer, Jesse Silverman, Carol Scavarda   +2 more
exaly   +3 more sources

Some of the next articles are maybe not open access.

Related searches:

Screening and Management of PTLD

Transplantation, 2023
Posttransplant lymphoproliferative disorder (PTLD) represents a heterogeneous group of lymphoproliferative diseases occurring in the setting of immunosuppression following hematopoietic stem cells transplant and solid organ transplantation. Despite its overall low incidence, PTLD is a serious complication following transplantation, with a mortality ...
Lorenzo, Zaffiri, Eileen T, Chambers
openaire   +2 more sources

Guidelines for Lyme borreliosis: post-treatment Lyme disease syndrome (PTLDS).

Infectious Diseases Now
International audiencePersistent symptoms following appropriate treatment of confirmed Lyme borreliosis (LB) require a systematic clinical reassessment.
Cédric Lemogne, Y Hansmann, C Eldin
exaly   +2 more sources

Das pädiatrische PTLD-Register (Ped-PTLD-Register)

Der Nephrologe, 2009
Lymphoproliferative Erkrankungen (PTLD) sind seltene, doch schwere Komplikationen der immunsuppressiven Therapie nach Organtransplantation. Sie entstehen meist auf dem Boden einer gestorten Immunantwort gegenuber Epstein-Barr-Virus (EBV). Im Kindesalter werden pro Jahr in Deutschland etwa 15–20 Kinder mit PTLD diagnostiziert.
B. Maecker-Kolhoff, C. Klein
openaire   +1 more source

Definitions and Pathology of PTLD

2021
The post-transplant lymphoproliferative disorders (PTLDs) are a spectrum of lymphoid and plasmacytic proliferations that in about 60–80% of cases are associated with the Epstein-Barr virus (EBV). They are categorized into four major categories using the 2016 World Health Organization (WHO) classification.
Steven H. Swerdlow, Steven A. Webber
openaire   +1 more source

Posttransplant Lymphoproliferative Disorders (PTLDs)

2020
Posttransplant lymphoproliferative disorders (PTLDs) are lymphoid or plasmacytic proliferations that develop in solid organ, bone marrow, or stem cell allograft recipients in a setting of immunosuppression. PTLDs’ spectrum ranges from usually EBV-driven reactive lymphoid/plasmacytic proliferations to EBV+ or EBV− monoclonal lymphomas or plasmacytic ...
exaly   +2 more sources

Classic Hodgkin lymphoma post-transplant lymphoproliferative disorders (PTLD) are often preceded by discordant PTLD subtypes

Leukemia & Lymphoma, 2020
Classic Hodgkin lymphoma (CHL) is the rarest post-transplant lymphoproliferative disorder (PTLD) subtype. Few cases of patients with metachronous discordant PTLD episodes including CHL-PTLD have been reported, but the incidence of and risk factors for this phenomenon are unknown.
Ryan J. Stubbins, Curtis Mabilangan, Marta Rojas-Vasquez, Raymond L. Lai, James Zhu, Jutta P. Preiksaitis, Anthea C. Peters   +6 more
openaire   +2 more sources

PTLD after Lung Transplantation

2021
The specter of post-transplant lymphoproliferative disorder (PTLD) hangs over the lung transplant population like the legendary sword of Damocles, as an ever-present danger which is even more apparent in the pediatric population. The major risk factor, of course, is primary Epstein-Barr virus infection usually transmitted via a seropositive donor into ...
Allan R. Glanville, Gary Visner
openaire   +1 more source